Filing Details

Accession Number:
0001209191-20-051614
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-22 21:20:03
Reporting Period:
2020-09-18
Accepted Time:
2020-09-22 21:20:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1438533 Retrophin Inc. RTRX Pharmaceutical Preparations (2834) 262383102
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1579649 L. Noah Rosenberg C/O Retrophin, Inc.
3721 Valley Centre Drive, Suite 200
San Diego CA 92130
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-18 3,000 $0.00 29,055 No 4 A Direct
Common Stock Disposition 2020-09-22 750 $18.59 28,305 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled.
  2. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligationthat occurred upon the vesting of performance restricted stock units.